Market Research Future

Esophageal Cancer Market Overview, Leading Player & Future Forecast to 2023


Pune, India -- (SBWIRE) -- 06/11/2018 -- Esophageal Cancer Market Scenario:

Cancer is the leading and second largest cause of death across the globe. The disease is characterized by disordered and deregulated cellular and stromal explosion along with reduced cell death and growth factor deprivation, and such other factors. Esophageal cancer is cancer arising from the esophagus which is the food pipe connecting the throat and the stomach. Symptoms of esophageal cancer include difficulty and in swallowing which causes reduced food intake and weight loss, enlarged lymph nodes, cough which includes blood etc. The two main sub-types of esophageal cancer are esophageal squamous-cell carcinoma which arises from the epithelial cells and esophageal adenocarcinoma which arises from the glandular cells. These two cancers have different primary causes and different rates of prevalence. Esophageal squamous-cell carcinoma is more common in the developing world, and esophageal adenocarcinoma is more common in the developed world. Causes of the squamous-cell carcinoma include tobacco, alcohol, very hot drinks, poor diet, and chewing betel nut while the most common causes of the adenocarcinoma are smoking tobacco, obesity, and acid reflux.

Report with Discount Available  @

Considering all these factors the market for esophageal cancer is expected to reach $ 1000.1 million by the end of 2023, this market is projected to growing at a CAGR of ~ 8.7 % during 2017-2023.

 Intended Audience

Global Esophageal cancer solutions providers, manufacturers & suppliers
Research and development (R&D) companies
Market research and consulting service providers
Academic institutes and universities
Key players of Global Esophageal cancer Market:

Key players profiled in the report are Amgen, Eli Lilly and Company, F. Hoffmann-La Roche, Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, GlaxoSmithKline Plc., Novartis AG, Johnson & Johnson, Gilead Sciences, Merck & Co. and others.
The global esophageal cancer market is segmented on the basis of type. Based on the type, the market has been segmented as esophageal squamous-cell carcinoma, esophageal adenocarcinoma and others. Based on the phases, the market has been segmented as phase I, phases II and phases III. Based on the treatment, the market has been segmented as surgery, chemotherapy and radiotherapy and other.

Request Full Report @

Regional Analysis

US accounts for the maximum market share due to favorable reimbursement scenario and greater expenditure on healthcare. Europe is the second largest market due to large disposable income and rising awareness. Asia pacific region will be the fastest region because of large unmet needs which will be led by China and India. The Middle East and Africa market will be led by the gulf nations particularly Saudi Arabia and UAE. The poor regions of Africa is expected to be a laggard due to poor economic and political conditions.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.